"Tolerance" assays: the physician's guide to safe weaning of immunosuppression?

Transplantation Reviews

Volumn 20, Issue 4, 2006, Pages 208-221

  Lau, Audrey H ^a,b   Turnquist, Heth R ^a,b   Tokita, Daisuke ^a,b   Zeevi, Adriana ^a,b   Mazariegos, George V ^a,c   Thomson, Angus W ^a,b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; AZATHIOPRINE; CD28 ANTIGEN; CD4 ANTIGEN; CHEMOKINE RECEPTOR; CYCLOSPORIN; HLA G ANTIGEN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ALPHA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; STEROID; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR FOXP3;

ALLOGRAFT; ANTIGEN EXPRESSION; ARTICLE; CANCER; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL ASSAY; CELL MEDIATED LYMPHOLYSIS; CYTOTOXIC T LYMPHOCYTE; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; DNA POLYMORPHISM; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSPOT ASSAY; GENE EXPRESSION PROFILING; GRAFT REJECTION; HELPER CELL; HUMAN; HYPERTENSION; IMMUNE RESPONSE; IMMUNOLOGICAL MONITORING; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; INFECTION; KIDNEY DYSFUNCTION; MEDICAL TECHNOLOGY; MICROCHIMERISM; MIXED LYMPHOCYTE REACTION; MOLECULAR IMAGING; NATURAL KILLER CELL; NONHUMAN; PHYSICIAN; PREDICTIVE VALIDITY; PROLYMPHOCYTE; PROTEOMICS; RELIABILITY; SAFETY; SENSITIVITY AND SPECIFICITY; SUPPRESSOR CELL; TRANSPLANTATION TOLERANCE; VALIDATION PROCESS;

EID: 33751077036     PISSN: 0955470X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trre.2006.09.001     Document Type: Article

References (183)

1. Sayegh M., and Carpenter C. Transplantation 50 years later-progress, challenges, and promises. N Engl J Med 351 (2004) 2761-2766
2. Taylor A.L., Watson C.J., and Bradley J.A. Immunosuppressive agents in solid organ transplantation: mechanisms of action and therapeutic efficacy. Crit Rev Oncol Hematol 56 (2005) 23-46
3. Fine R.N. Growth following solid-organ transplantation. Pediatr Transplant 6 (2002) 47-52
4. Campbell K.M., Yazigi N., Ryckman F.C., Alonso M., Tiao G., Balistreri W.F., et al. High prevalence of renal dysfunction in long-term survivors after pediatric liver transplantation. J Pediatr 148 (2006) 475-480
5. Krull K., Fuchs C., Yurk H., Boone P., and Alonso E. Neurocognitive outcome in pediatric liver transplant recipients. Pediatr Transplant 7 (2003) 111-118
6. Qvist E., Pihko H., Fagerudd P., Valanne L., Lamminranta S., Karikoski J., et al. Neurodevelopmental outcome in high-risk patients after renal transplantation in early childhood. Pediatr Transplant 6 (2002) 53-62
7. Bucuvalas J.C., Campbell K.M., Cole C.R., and Guthery S.L. Outcomes after liver transplantation: keep the end in mind. J Pediatr Gastroenterol Nutr 43 (2006) S41-S48
8. Renoult E., Buteau C., Lamarre V., Turgeon N., and Tapiero B. Infectious risk in pediatric organ transplant recipients: is it increased with the new immunosuppressive agents?. Pediatr Transplant 9 (2005) 470-479
9. Blaha P., Bigenzahn S., Koporc Z., Schmid M., Langer F., Selzer E., et al. The influence of immunosuppressive drugs on tolerance induction through bone marrow transplantation with costimulation blockade. Blood 102 (2003) 2886-2893
10. Lechler R.I., Sykes M., Thomson A.W., and Turka L.A. Organ transplantation-how much of the promise has been realized?. Nat Med 11 (2005) 605-613
11. Wells A.D., Li X.C., Li Y., Walsh M.C., Zheng X.X., Wu Z., et al. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med 5 (2005) 1303-1307
12. Kean L.S., Gangappa S., Pearson T.C., and Larsen C.P. Transplant tolerance in non-human primates: progress, current challenges and unmet needs. Am J Transp 6 (2006) 884-893
13. Mazariegos G.V., Reyes J., Marino I.R., Demetris A.J., Flynn B., Irish W., et al. Weaning of immunosupression in liver transplant recipients. Transplantation 63 (1997) 243-249
14. Roussey-Kesler G., Giral M., Moreau A., Subra J.F., Legendre C., Noel C., et al. Clinical operational tolerance after kidney transplantation. Am J Transp 6 (2006) 736-746
15. Starzl T.E., Demetris A.J., Trucco M., Murase N., Ricordi C., Ildstad S., et al. Cell migration and chimerism after whole organ transplantation: the basis of graft acceptance. Hepatology 17 (1993) 1127-1152
16. Strober S., Benike C., Krishnaswamy S., Engleman E., and Grumet F. Clinical transplantation tolerance twelve years after prospective withdrawal of immunosuppressive drugs: studies of chimerism and anti-donor reactivity. Transplantation 69 (2000) 1549-1554
17. Ansari M.J., and Sayegh M.H. Clinical transplantation tolerance: the promise and challenges. Kidney Int 65 (2004) 1560-1563
18. Goulmy E., Stijnen T., Groenewoud A., Persijn G., Blokland E., Pool J., et al. Renal transplant patients monitored by the cell-mediated lympholysis assay. Evaluation of its clinical value. Transplantation 48 (1989) 559-563
19. Ishido N., Matsuoka J., Fujiwara T., Tanaka S., Matsuno T., and Tanaka N. Donor specific hyporesponsiveness in a clinically tolerant renal transplant recipient. Transplant Proc 31 (1999) 2880-2882
20. Li Y., Koshiba T., Yoshizawa A., Yonekawa Y., Masuda K., Ito A., et al. Analyses of peripheral blood mononuclear cells in operational tolerance after pediatric living donor liver transplantation. Am J Transp 4 (2004) 2118-2125
21. +T cells/FOXP3 patterns in chronic rejection and operational drug-free tolerance. Transplantation 81 (2006) 398-407
22. Chung S.W., Yoshida E.M., Cattral M.S., Hu Y., and Gorczynski R.M. Donor-specific stimulation of peripheral blood mononuclear cells from recipients of orthotopic liver transplants is associated, in the absence of rejection, with type-2 cytokine production. Immunol Lett 63 (1998) 91-96
23. Weimar W., Rischen-Vos J., de Kuiper P., Gregoor P., Ijzermans J., van Besouw N., et al. Tapering immunosuppression in recipients of living donor kidney transplants. Nephrol Dial Transplant 19 (2004) iv61-iv63
24. van Besouw N., van der Mast B., de Kuiper P., Smak Gregoor P., Vaessen L., Ijzermans J., et al. Donor-specific T-cell reactivity identifies kidney transplant patients in whom immunosuppressive therapy can be safely reduced. Transplantation 70 (2000) 136-143
25. Einecke G., Fairhead T., Hidalgo L.G., Sis B., Turner P., Zhu L.-F., et al. Tubulitis and epithelial cell alterations in mouse kidney transplant rejection are independent of CD103, perforin or granzymes A/B. Am J Transp 6 (2006) 2109-2120
26. Reding R., Gras J., Truong D., Wieers G., and Latinne D. The immunological monitoring of alloreactive responses in liver transplant recipients: a review. Liver Transplant 12 (2006) 373-383
27. Thomson A.W., Lu L., Murase N., Demetris A.J., Rao A.S., and Starzl T.E. Microchimerism, dendritic cell progenitors and transplantation tolerance. Stem Cells 13 (1995) 622-639
28. Bettens F., Tiercy J., Campanile N., Giostra E., Majno P., Rubbia L., et al. Microchimerism after liver transplantation: absence of rejection without abrogation of anti-donor cytotoxic T-lymphocyte-mediated alloreactivity. Liver Transplant 11 (2005) 290-297
29. Schlitt H., Hundrieser J., Ringe B., and Pichlmayr R. Donor-type microchimerism associated with graft rejection eight years after liver transplantation. N Engl J Med 330 (1994) 646-647
30. Burlingham W., Jankowska-Gan E., VanBuskirk A., Orosz C., Lee J., and Kusaka S. Loss of tolerance to a maternal kidney transplant is selective for HLA class II: evidence from trans-vivo DTH and alloantibody analysis. Hum Immunol 61 (2000) 1395-1402
31. Carrodeguas L., Orosz C., Waldman W., Sedmak D., Adams P., and VanBuskirk A. Trans vivo analysis of human delayed-type hypersensitivity reactivity. Hum Immunol 60 (1999) 640-651
32. Derks R., and Burlingham W. In vitro parameters of donor-antigen-specific tolerance. Curr Opin Immunol 17 (2005) 560-564
33. Orosz C.G. Detecting donor-reactive immune regulation in transplant patients. ASHI Quarterly 27 (2003) 8-10
34. Rodriguez D., Jankowska-Gan E., Haynes L., Leverson G., Munoz A., Heisey D., et al. Immune regulation and graft survival in kidney transplant recipients are both enhanced by human leukocyte antigen matching. Am J Transp 4 (2004) 537-543
35. VanBuskirk A., Burlingham W., Jankowska-Gan E., Chin T., Kusaka S., Geissler F., et al. Human allograft acceptance is associated with immune regulation. J Clin Invest 106 (2000) 145-155
36. Barratt-Boyes S., and Thomson A. Dendritic cells: tools and targets for transplant tolerance. Am J Transp 5 (2005) 2807-2813
37. Morelli A.E., and Thomson A.W. Dendritic cells: regulators of alloimmunity and opportunities for tolerance induction. Immunol Rev 196 (2003) 125-146
38. Steinman R.M., Hawiger D., and Nussenzweig M.C. Tolerogenic dendritic cells. Annu Rev Immunol 21 (2003) 685-711
39. Liu Y., Kanzler H., Soumelis V., and Gilliet M. Dendritic cell lineage, plasticity and cross-regulation. Nat Immunol 2 (2001) 585-589
40. Liu Y.J. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 23 (2005) 275-306
41. Pulendran B., Smith J.L., Caspary G., Brasel K., Pettit D., Maraskovsky E., et al. Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc Natl Acad Sci U S A 96 (1999) 1036-1041
42. + T cell anergy by peripheral blood DC2 precursors. Eur J Immunol 31 (2001) 2547-2557
43. Robinson S., Patterson S., English N., Davies D., Knight S., and Reid C. Human peripheral blood contains two distinct lineages of dendritic cells. Eur J Immunol 29 (1999) 2769-2778
44. Rissoan M.C., Soumelis V., Kadowaki N., Grouard G., Briere F., de Waal Malefyt R., et al. Reciprocal control of T helper cell and dendritic cell differentiation. Science 283 (1999) 1183-1186
45. Gilliet M., and Liu Y.J. Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. J Exp Med 195 (2002) 695-704
46. + regulatory T cells. J Immunol 173 (2004) 4433-4442
47. Abe M., Colvin B.L., and Thomson A.W. Plasmacytoid dendritic cells: in vivo regulators of alloimmune reactivity. Transplant Proc 37 (2005) 4119-4121
48. + dendritic cells endowed with type 1 interferon production capacity and tolerogenic potential. Blood 100 (2002) 383-390
49. + DC, with a plasmacytoid phenotype, induce differentiation and support function of T cells with regulatory properties. Immunology 108 (2003) 481-492
50. Wakkach A., Fournier N., Brun V., Breittmayer J., Cottrez F., and Groux H. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity 18 (2003) 605-617
51. Abe M., Wang Z., De Creus A., and Thomson A.W. Plasmacytoid dendritic cell precursors induce allogeneic T-cell hyporesponsiveness and prolong heart graft survival. Am J Transp 5 (2005) 1808-1819
52. Bjorck P., Coates P.T., Wang Z., Duncan F.J., and Thomson A.W. Promotion of long-term heart allograft survival by combination of mobilized donor plasmacytoid dendritic cells and anti-CD154 monoclonal antibody. J Heart Lung Transplant 24 (2005) 1118-1120
53. Fugier-Vivier I.J., Rezzoug F., Huang Y., Graul-Layman A.J., Schanie C.L., Xu H., et al. Plasmacytoid precursor dendritic cells facilitate allogeneic hematopoietic stem cell engraftment. J Exo 201 (2005) 373-383
54. Ochando J.C., Homma C., Yang Y., Hidalgo A., Garin A., Tacke F., et al. Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts. Nat Immunol 7 (2006) 652-662
55. Mazariegos G.V., Zahorchak A., Reyes J., Ostrowski L., Flynn B., Zeevi A., et al. Dendritic cell subset ratio in peripheral blood correlates with successful withdrawal of immunosuppression in liver transplant patients. Am J Transp 3 (2003) 689-696
56. Mazariegos G.V., Zahorchak A., Reyes J., Chapman H., Zeevi A., and Thomson A. Dendritic cell subset ratio in tolerant, weaning and non-tolerant liver recipients is not affected by extent of immunosuppression. Am J Transp 5 (2005) 314-322
57. + T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 192 (2000) 1213-1222
58. Ciubotariu R., Vasilescu R., Ho E., Cinti P., Cancedda C., Poli L., et al. Detection of T suppressor cells in patients with organ allografts. Hum Immunol 62 (2001) 15-20
59. - T cells in heart transplant recipients. Hum Immunol 64 (2003) 31-37
60. Chang C., Ciubotariu R., Manavalan J., Yuan J., Colovai A., Piazza F., et al. Tolerization of dendritic cells by T(S) cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat Immunol 3 (2002) 237-243
61. Cortesini N., Colovai A., Manavalan J., Galluzzo S., Naiyer A., Liu J., et al. Role of regulatory and suppressor T-cells in the induction of ILT3+ ILT4+ tolerogenic endothelial cells in organ allografts. Transpl Immunol 13 (2004) 73-82
62. Dallman M.J. Cytokines and transplantation: Th1/Th2 regulation of the immune response to solid organ transplants in the adult. Curr Opin Immunol 7 (1995) 632-638
63. Li L., Sad S., Kagi D., and Mosmann T.R. CD8Tc1 and Tc2 cells secrete distinct cytokine patterns in vitro and in vivo but induce similar inflammatory reactions. J Immunol 158 (1997) 4152-4161
64. + T cells. Transplantation 161 (1998) 5236-5244
65. Matesic D., Lehmann P.V., and Heeger P.S. High-resolution characterization of cytokine-producing alloreactivity in naive and allograft-primed mice. Transplantation 65 (1998) 906-914
66. Gebauer B.S., Hricik D.E., Atallah A., Bryan K., Riley J., Tary-Lehmann M., et al. Evolution of the enzyme-linked immunosorbent spot assay for post-transplant alloreactivity as a potentially useful immune monitoring tool. Am J Transp 2 (2002) 857-866
67. Hricik D.E., Rodriguez V., Riley J., Bryan K., Tary-Lehmann M., Greenspan N., et al. Enzyme linked immunosorbent spot (ELISPOT) assay for interferon-gamma independently predicts renal function in kidney transplant recipients. Am J Transp 3 (2003) 878-884
68. Tary-Lehmann M., Hricik D.E., Justice A.C., Potter N.S., and Heeger P.S. Enzyme-linked immunosorbent assay spot detection of interferon-gamma and interleukin 5-producing cells as a predictive marker for renal allograft failure. Transplantation 66 (1998) 219-224
69. Valujskikh A., Matesic D., Gilliam A., Anthony D., Haqqi T.M., and Heeger P.S. T cells reactive to a single immunodominant self-restricted allopeptide induce skin graft rejection in mice. J Clin Invest 101 (1998) 1398-1407
70. Poggio E.D., Roddy M., Riley J., Clemente M., Hricik D.E., Starling R., et al. Analysis of immune markers in human cardiac allograft recipients and association with coronary artery vasculopathy. J Heart Lung Transplant 24 (2005) 1606-1613
71. Bellisola G., Tridente G., Nacchia F., Fior F., and Boschiero L. Monitoring of cellular immunity by interferon-gamma enzyme-linked immunosorbent spot assay in kidney allograft recipients: preliminary results of a longitudinal study. Transplant Proc 38 (2006) 1014-1017
72. Kowalski R., Post D., Schneider M.C., Britz J., Thomas J., Deierhoi M., et al. Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant 17 (2003) 77-88
73. Kowalski R.J., Post D.R., Mannon R.B., Sebastian A., Wright H.I., Sigle G., et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation 82 (2006) 663-668
74. Thai N., Blisard D., Basu A., Tom K., Tan H., Bentlejewski C., et al. Pancreas transplantation under Campath-1H and Tacrolimus: correlation between low T cell responses and infection. Am J Transp 6 Suppl 2 (2006) 104 [abstr]
75. Gautam A., Fischer S., Gohh R.Y., Yango A., Monaco A.P., and Morrissey P.E. Monitoring cell mediated immunity during immunosuppression reduction for serious infection. Am J Transp 6 Suppl 2 (2006) 150 [abstr]
76. Valero R., Sanchez-Velasco P., Rodrigo E., Ruiz J.C., Leyva F., and Arias M. Assessment about risk of infection in kidney transplant by measuring the concentration of ATP from CD4 cells following stimulation by Cylex. Am J Transp 6 Suppl 2 (2006) 486 [abstr]
77. Zeevi A., Britz J.A., Bentlejewski C.A., Guaspari D., Tong W., Bond G., et al. Monitoring immune function during tacrolimus tapering in small bowel transplant recipients. Transpl Immunol 15 (2005) 17-24
78. Ciubotariu R., Liu Z., Colovai A.I., Ho E., Itescu S., Ravalli S., et al. Persistent allopeptide reactivity and epitope spreading in chronic rejection of organ allografts. J Clin Invest 101 (1998) 398-405
79. Barth C., Von Menges A., Zanker B., Lammerding P., Stachowski J., and Baldamus C.A. Restricted T cell Vb repertoire in renal allografts during acute and chronic rejection. Kidney Int 50 (1996) 2020-2026
80. Hall B.L., Hand S.L., Alter M.D., Kirk A.D., and Finn O.J. Variables affecting the T cell receptor Vb repertoire heterogeneity of T cells infiltrating human renal allografts. Transpl Immunol 1 (1993) 217-227
81. Hand S.L., Hall B.L., and Finn O.J. T-cell receptor gene usage and expression in renal allograft-derived T-cell lines. Hum Immunol 28 (1990) 82-95
82. Kolopp-Sarda M.N., Renoult E., Gregoire M.J., Bene M.C., Kessler M., and Faure G.C. Increased usage of TCR V-b8 in kidney transplant recipients with aberrant immune reconstitution and clinical complications. Transplantation 67 (1999) 1441-1446
83. Gagne K., Brouard S., Giral M., Sebille F., Moreau A., Guillet M., et al. Highly altered Vb repertoire of T cells infiltrating long-term rejected kidney allografts. J Immunol 164 (2000) 1553-1563
84. Guillet M., Brouard S., Gagne K., Sebille F., Cuturi M.C., Delsuc M.A., et al. Different qualitative and quantitative regulation of Vb TCR transcripts during early acute allograft rejection and tolerance induction. J Immunol 168 (2002) 5088-5095
85. Brouard S., Dupont A., Giral M., Louis S., Lair D., Braudeau C., et al. Operationally tolerant and minimally immunosuppressed kidney recipients display strongly altered blood T-cell clonal regulation. Am J Transp 5 (2005) 330-340
86. Gebel H.M., Bray R.A., and Nickerson P. Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: contraindication vs. risk. Am J Transp 3 (2003) 1488-1500
87. Itescu S., Tung T.C., Burke E.M., Weinberg A., Moazami N., Artrip J.H., et al. Preformed IgG antibodies against major histocompatibility complex class II antigens are major risk factors for high-grade cellular rejection in recipients of heart transplantation. Circulation 98 (1998) 786-793
88. McKenna R.M., Takemoto S.K., and Terasaki P.I. Anti-HLA antibodies after solid organ transplantation. Transplantation 69 (2000) 319-326
89. Smith J.D., Danskine A.J., Laylor R.M., Rose M., and Yacoub M. The effect of panel reactive antibodies and the donor specific crossmatch on graft survival after heart and heart-lung transplantation. Transpl Immunol 1 (1993) 60-65
90. Suciu-Foca N., Reed E., D'Agati V., Ho E., Cohen D., Benvenisty A., et al. Soluble HLA antigens, anti-HLA antibodies, and antiidiotypic antibodies in the circulation of renal transplant recipients. Transplantation 51 (1991) 593-601
91. Girnita A.L., Duquesnoy R., Yousem S.A., Iacono A.T., Corcoran T.E., Buzoianu M., et al. HLA-specific antibodies are risk factors for lymphocytic bronchiolitis and chronic lung allograft dysfunction. Am J Transp 5 (2005) 131-138
92. Palmer S.M., Davis R.D., Hadjiliadis D., Hertz M.I., Howell D.N., Ward F.E., et al. Development of an antibody specific to major histocompatibility antigens detectable by flow cytometry after lung transplant is associated with bronchiolitis obliterans syndrome. Transplantation 74 (2002) 799-804
93. Sundaresan S., Mohanakumar T., Smith M., Trulock E., Lynch J., Phelan D., et al. HLA-A locus mismatches and development of antibodies to HLA after lung transplantation correlate with the development of bronchiolitis obliterans syndrome. Transplantation 65 (1998) 648-653
94. Mulder A., Kardol M.J., Kamp J., Uit Het Broek C., Schreuder G., Doxiadis I., et al. Determination of the frequency of HLA antibody secreting B-lymphocytes in alloantigen sensitized individuals. Clin Exp Immunol 124 (2001) 9-15
95. Carosella E., Moreau P., Le Maoult J., Le Discorde M., Dausset J., and Rouas-Freiss N. HLA-G molecules: from maternal-fetal tolerance to tissue acceptance. Adv Immunol (2003) 81
96. Creput C., Durrbach A., Menier C., Guettier C., Samuel D., Dausset J., et al. Human leukocyte antigen-G (HLA-G) expression in biliary epithelial cells is associated with allograft acceptance in liver-kidney transplantation. J Hepatol 39 (2003) 587-594
97. Lila N., Amrein C., Guillemain R., Chevalier P., Latremouille C., Fabiani J., et al. Human leukocyte antigen-G expression after heart transplantation is associated with a reduced incidence of rejection. Circulation 105 (2002) 1949-1954
98. Riteau B., Rouas-Freiss N., Menier C., Paul P., Dausset J., and Carosella E. HLA-G2, -G3, and -G4 isoforms expressed as nonmature cell surface glycoproteins inhibit NK and antigen-specific CTL cytolysis. J Immunol 166 (2001) 5018-5026
99. + T cell regulatory mechanism. Proc Natl Acad Sci U S A 98 (2001) 12150-12155
100. LeMaoult J., Krawice-Radanne I., Dausset J., and Carosella E. HLA-G1-expressing antigen-presenting cells induce immunosuppressive CD4+ T cells. Proc Natl Acad Sci U S A 101 (2004) 7064-7069
101. LeMaoult J., Zafaranloo K., Le Danff C., and Carosella E. HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells. FASEB J 19 (2005) 662-664
102. Ristich V., Liang S., Zhang W., Wu J., and Horuzsko A. Tolerization of dendritic cells by HLA-G. Eur J Immunol 35 (2005) 1133-1142
103. Le Rond S., Azema C., Krawice-Radanne I., Durrbach A., Guettier C., Carosella E., et al. Evidence to support the role of HLA-G5 in allograft acceptance through induction of immunosuppressive/regulatory T cells. J Immunol 176 (2006) 3266-3276
104. Bidwell J., Keen L., Gallagher G., Kimberly R., Huizinga T., McDermott M., et al. Cytokine gene polymorphism in human disease: on-line databases. Genes Immun 1 (1999) 3-19
105. Fugger L., Morling N., Ryder L.P., Georgsen J., Jakobsen B., Svejgaard A., et al. NcoI restriction fragment length polymorphism (RFLP) of the tumor necrosis factor (TNF alpha) region in four autoimmune diseases. Tissue Antigens 34 (1989) 17-22
106. Jin P., Panelli M., Marincola F., and Wang E. Cytokine polymorphism and its possible impact on cancer. Immunol Res 30 (2004) 181-190
107. Stuber F., Petersen M., Bokelmann F., and Schade U. A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis. Crit Care Med 24 (1996) 381-384
108. Haukim N., Bidwell J.L., Smith A.J., Keen L., Gallagher G., Kimberly R., et al. Cytokine gene polymorphism in human disease: on-line databases, supplement 2. Genes Immun 3 (2002) 313-330
109. Holweg C.T., Weimar W., Uitterlinden A.G., and Baan C.C. Clinical impact of cytokine gene polymorphisms in heart and lung transplantation. J Heart Lung Transplant 23 (2004) 1017-1026
110. Marder B., Schroppel B., and Murphy B. Genetic variability and transplantation. Curr Opin Urol 13 (2003) 81-89
111. Marshall S.E., and Welsh K.I. The role of cytokine polymorphisms in rejection after solid organ transplantation. Genes Immun 2 (2001) 297-303
112. Mytilineos J., Laux G., and Opelz G. Relevance of IL10, TGFb1, TNFa, and IL4Ra gene polymorphisms in kidney transplantation: a collaborative transplant study report. Am J Transp 4 (2004) 1684-1690
113. Poole K.L., Gibbs P.J., Evans P.R., Sadek S.A., and Howell W.M. Influence of patient and donor cytokine genotypes on renal allograft rejection: evidence from a single centre study. Transpl Immunol 8 (2001) 259-265
114. Uboldi de Capei M., Dametto E., Fasano M.E., Messina M., Pratico' L., Rendine S., et al. Cytokines and chronic rejection: a study in kidney transplant long-term survivors. Transplantation 77 (2004) 548-552
115. Hackstein H., Kluter H., Fricke L., Hoyer J., and Bein G. The IL-4 receptor a-chain variant Q576R is strongly associated with decreased kidney allograft survival. Tissue Antigens 54 (1999) 471-477
116. Hutchings A., Guay-Woodford L., Thomas J.M., Young C.J., Purcell W.M., Pravica V., et al. Association of cytokine single nucleotide polymorphisms with B7 costimulatory molecules in kidney allograft recipients. Pediatr Transp 6 (2002) 69-77
117. Asderakis A., Sankaran D., Dyer P., Johnson R., Pravica V., Sinnott P., et al. Association of polymorphisms in the human interferon-gamma and interleukin-10 gene with acute and chronic kidney transplant outcome: the cytokine effect on transplantation. Transplantation 71 (2001) 674-677
118. Awad M.R., Webber S., Boyle G., Sturchioc C., Ahmed M., Martell J., et al. The effect of cytokine gene polymorphisms on pediatric heart allograft outcome. J Heart Lung Transplant 20 (2001) 625-630
119. Warle M.C., Metselaar H.J., Hop W.C., and Tilanus H.W. Cytokine gene polymorphisms and acute liver graft rejection: a meta-analysis. Liver Transplant 11 (2005) 19-26
120. Awad M., Pravica V., Perrey C., El Gamel A., Yonan N., Sinnott P.J., et al. CA repeat allele polymorphism in the first intron of the human interferon-gamma gene is associated with lung allograft fibrosis. Hum Immunol 60 (1999) 343-346
121. Lu K.C., Jaramillo A., Lecha R.L., Schuessler R.B., Aloush A., Trulock E.P., et al. Interleukin-6 and interferon-gamma gene polymorphisms in the development of bronchiolitis obliterans syndrome after lung transplantation. Transplantation 74 (2002) 1297-1302
122. Ternstrom L., Jeppsson A., Ricksten A., and Nilsson F. Tumor necrosis factor gene polymorphism and cardiac allograft vasculopathy. J Heart Lung Transplant 24 (2005) 433-438
123. Mazariegos G.V., Reyes J., Webber S.A., Thomson A.W., Ostrowski L., Abmed M., et al. Cytokine gene polymorphisms in children successfully withdrawn from immunosuppression after liver transplantation. Transplantation 73 (2002) 1342-1345
124. Fischereder M., Luckow B., Hocher B., Wuthrich R.P., Rothenpieler U., Schneeberger H., et al. CC chemokine receptor 5 and renal-transplant survival. Lancet 357 (2001) 1758-1761
125. Shieh B., Liau Y.E., Hsieh P.S., Yan Y.P., Wang S.T., and Li C. Influence of nucleotide polymorphisms in the CCR2 gene and the CCR5 promoter on the expression of cell surface CCR5 and CXCR4. Int Immunol 12 (2000) 1311-1318
126. Abdi R., Tran T.B., Sahagun-Ruiz A., Murphy P.M., Brenner B.M., Milford E.L., et al. Chemokine receptor polymorphism and risk of acute rejection in human renal transplantation. J Am Soc Nephrol 13 (2002) 754-758
127. Kruger B., Schroppel B., Ashkan R., Marder B., Zulke C., Murphy B., et al. A monocyte chemoattractant protein-1 (MCP-1) polymorphism and outcome after renal transplantation. J Am Soc Nephrol 13 (2002) 2585-2589
128. Schroppel B., Fischereder M., Lin M., Marder B., Schiano T., Kramer B.K., et al. Analysis of gene polymorphisms in the regulatory region of MCP-1, RANTES, and CCR5 in liver transplant recipients. J Clin Immunol 22 (2002) 381-385
129. Reiser H., and Stadecker M.J. Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases. N Engl J Med 335 (1996) 1369-1377
130. Sayegh M.H., and Turka L.A. The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med 338 (1998) 1813-1821
131. Khoury S.J., Akalin E., Chandraker A., Turka L.A., Linsley P.S., Sayegh M.H., et al. CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. J Immunol 155 (1995) 4521-4524
132. Kirk A.D., Harlan D.M., Armstrong N.N., Davis T.A., Dong Y., Gray G.S., et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A 94 (1997) 8789-8794
133. Larsen C.P., Elwood E.T., Alexander D.Z., Ritchie S.C., Hendrix R., Tucker-Burden C., et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 381 (1996) 434-438
134. Krummel M.F., and Allison J.P. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 182 (1995) 459-465
135. Walunas T.L., Lenschow D.J., Bakker C.Y., Linsley P.S., Freeman G.J., Green J.M., et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1 (1994) 405-413
136. Deichmann K., Heinzmann A., Bruggenolte E., Forster J., and Kuehr J. An Mse I RFLP in the human CTLA4 promotor. Biochem Biophys Res Commun 225 (1996) 817-818
137. Harper K., Balzano C., Rouvier E., Mattei M.G., Luciani M.F., and Golstein P. CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location. J Immunol 147 (1991) 1037-1044
138. Polymeropoulos M.H., Xiao H., Rath D.S., and Merril C.R. Dinucleotide repeat polymorphism at the human CTLA4 gene. Nucleic Acids Res 19 (1991) 4018
139. Marder B.A., Schroppel B., Lin M., Schiano T., Parekh R., Tomer Y., et al. The impact of costimulatory molecule gene polymorphisms on clinical outcomes in liver transplantation. Am J Transp 3 (2003) 424-431
140. Slavcheva E., Albanis E., Jiao Q., Tran H., Bodian C., Knight R., et al. Cytotoxic T-lymphocyte antigen 4 gene polymorphisms and susceptibility to acute allograft rejection. Transplantation 72 (2001) 935-940
141. Marin L.A., Moya-Quiles M.R., Miras M., Muro M., Minguela A., Bermejo J., et al. Evaluation of CD86 gene polymorphism at +1057 position in liver transplant recipients. Transpl Immunol 15 (2005) 69-74
142. Itoh N., Yonehara S., Ishii A., Yonehara M., Mizushima S., Sameshima M., et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66 (1991) 233-243
143. Krammer P.H. CD95's deadly mission in the immune system. Nature 407 (2000) 789-795
144. Marin L.A., Muro M., Moya-Quiles M.R., Miras M., Minguela A., Bermejo J., et al. Study of Fas (CD95) and FasL (CD178) polymorphisms in liver transplant recipients. Tissue Antigens 67 (2006) 117-126
145. Ducloux D., Deschamps M., Yannaraki M., Ferrand C., Bamoulid J., Saas P., et al. Relevance of Toll-like receptor-4 polymorphisms in renal transplantation. Kidney Int 67 (2005) 2454-2461
146. Fekete A., Viklicky O., Hubacek J.A., Rusai K., Erdei G., Treszl A., et al. Association between heat shock protein 70s and Toll-like receptor polymorphisms with long-term renal allograft survival. Transpl Int 19 (2006) 190-196
147. Arbour N.C., Lorenz E., Schutte B.C., Zabner J., Kline J.N., Jones M., et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 25 (2000) 187-191
148. Mansfield E.S., and Sarwal M.M. Arraying the orchestration of allograft pathology. Am J Transp 4 (2004) 853-862
149. Sarwal M.M. Chipping into the human genome: novel insights for transplantation. Immunol Rev (2006) 210
150. Scherer A., Krause A., Walker J.R., Korn A., Niese D., and Raulf F. Early prognosis of the development of renal chronic allograft rejection by gene expression profiling of human protocol biopsies. Transplantation 75 (2003) 1323-1330
151. Flechner S.M., Kurian S.M., Head S.R., Sharp S.M., Whisenant T.C., Zhang J., et al. Kidney transplant rejection and tissue injury by gene profiling of biopsies and peripheral blood lymphocytes. Am J Transp 4 (2004) 1475-1489
152. Hoffmann S.C., Hale D.A., Kleiner D.E., Mannon R.B., Kampen R.L., Jacobson L.M., et al. Functionally significant renal allograft rejection is defined by transcriptional criteria. Am J Transp 5 (2005) 573-581
153. Mas V.R., Maluf D.G., Archer K.J., Yanek K., King A., Cotterell A., et al. Study of mRNA growth factors in urinary cells of kidney transplant recipients as predictors of chronic allograft nephropathy. Transplantation 80 (2005) 1686-1691
154. Tatapudi R.R., Muthukumar T., Dadhania D., Ding R., Li B., Sharma V.K., et al. Noninvasive detection of renal allograft inflammation by measurements of mRNA for IP-10 and CXCR3 in urine. Kidney Int 65 (2004) 2390-2397
155. Matz M., Beyer J., Wunsch D., Mashreghi M.F., Seiler M., Pratschke J., et al. Early post-transplant urinary IP-10 expression after kidney transplantation is predictive of short- and long-term graft function. Kidney Int 69 (2006) 1683-1690
156. Muthukumar T., Dadhania D., Ding R., Snopkowski C., Naqvi R., Lee J.B., et al. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med 353 (2005) 2342-2351
157. Clarke W. Proteomic research in renal transplantation. Ther Drug Monit 28 (2006) 19-22
158. Mehra M.R. The emergence of genomic and proteomic biomarkers in heart transplantation. J Heart Lung Transplant 24 (2005) S213-S218
159. Mehra M.R., Benza R., Deng M.C., Russell S., and Webber S. Surrogate markers for late cardiac allograft survival. Am J Transp 4 (2004) 1184-1191
160. Traum A.Z., and Schachter A.D. Transplantation proteomics. Pediatr Transplant 9 (2005) 700-711
161. Park M.H., Uber P.A., Scott R.L., and Mehra M.R. B-Type natriuretic peptide in heart transplantation: an important marker of allograft performance. Heart Fail Rev 8 (2003) 359-363
162. Buckley M.G., Yacoub M.H., and Singer D.R. Investigation of the plasma concentrations and circulating forms of BNP and ANP in orthotopic cardiac transplant recipients. J Hum Hypertens 12 (1998) 825-826
163. Park M.H., Scott R.L., Uber P.A., Harris B.C., Chambers R., and Mehra M.R. Usefulness of B-type natriuretic peptide levels in predicting hemodynamic perturbations after heart transplantation despite preserved left ventricular systolic function. Am J Cardiol 90 (2002) 1326-1329
164. Mehra M.R., Uber P.A., Potluri S., Ventura H.O., Scott R.L., and Park M.H. Usefulness of an elevated B-type natriuretic peptide to predict allograft failure, cardiac allograft vasculopathy, and survival after heart transplantation. Am J Cardiol 94 (2004) 454-458
165. Eisenberg M.S., Chen H.J., Warshofsky M.K., Sciacca R.R., Wasserman H.S., Schwartz A., et al. Elevated levels of plasma C-reactive protein are associated with decreased graft survival in cardiac transplant recipients. Circulation 102 (2000) 2100-2104
166. Pethig K., Heublein B., Kutschka I., and Haverich A. Systemic inflammatory response in cardiac allograft vasculopathy: high-sensitive C-reactive protein is associated with progressive luminal obstruction. Circulation 102 (2000) III233-III236
167. Clarke W., Silverman B.C., Zhang Z., Chan D.W., Klein A.S., and Molmenti E.P. Characterization of renal allograft rejection by urinary proteomic analysis. Ann Surg 237 (2003) 660-664
168. O'Riordan E., Orlova T.N., Mei J.J., Butt K., Chander P.M., Rahman S., et al. Bioinformatic analysis of the urine proteome of acute allograft rejection. J Am Soc Nephrol 15 (2004) 3240-3248
169. Schaub S., Rush D., Wilkins J., Gibson I.W., Weiler T., Sangster K., et al. Proteomic-based detection of urine proteins associated with acute renal allograft rejection. J Am Soc Nephrol 15 (2004) 219-227
170. Wittke S., Haubitz M., Walden M., Rohde F., Schwarz A., Mengel M., et al. Detection of acute tubulointerstitial rejection by proteomic analysis of urinary samples in renal transplant recipients. Am J Transp 5 (2005) 2479-2488
171. Schaub S., Wilkins J.A., Antonovici M., Krokhin O., Weiler T., Rush D., et al. Proteomic-based identification of cleaved urinary β2-microglobulin as a potential marker for acute tubular injury in renal allografts. Am J Transp 5 (2005) 729-738
172. Kanderi T., Moore W.H., and Wendt J.A. Molecular imaging in transplantation: basic concepts and strategies for potential application. Nucl Med Commun 26 (2005) 947-955
173. Blankenberg F.G., Wen P., Dai M., Zhu D., Panchal S.N., Tait J.F., et al. Detection of early atherosclerosis with radiolabeled monocyte chemoattractant protein-1 in prediabeteic Zucker rats. Pediatr Transplant 31 (2001) 827-835
174. Ohtsuki K., Hayase M., Akashi K., Kopiwoda S., and Strauss H.W. Detection of monocyte chemoattractant protein-1 receptor expression in experimental atherosclerotic lesions: an autoradiographic study. Circulation 104 (2005) 203-208
175. Signore A., Chianelli M., Bei R., Oyen W., and Modesti A. Targeting cytokine/chemokine receptors: a challenge for molecular nuclear medicine. Eur J Nucl Med Mol Imaging 30 (2005) 149-156
176. Brem R.F., Schoonjans J.M., Kieper D.A., Majewski S., Goodman S., and Civelek C. High-resolution scintimammography: a pilot study. J Nucl Med 43 (2002) 909-915
177. De Vincentis G., Scopinaro F., Pani R., Pellegrini R., Soluri A., Ierardi M., et al. 99mTc MIBI scintimammography with a high resolution single tube gamma camera: preliminary study. Anticancer Res 17 (1997) 1627-1630
178. Blankenberg F.G. Molecular imaging: the latest generation of contrast agents and tissue characterization techniques. J Cell Biochem 90 (2003) 443-453
179. Britz-Cunningham S.H., and Adelstein S.J. Molecular targeting with radionuclides: state of the science. J Nucl Med 44 (2003) 1945-1961
180. Blankenberg F.G., and Strauss H.W. Non-invasive diagnosis of acute heart- or lung-transplant rejection using radiolabeled annexin V. Pediatr Transplant 29 (1999) 299-305
181. Kown M.H., Strauss H.W., Blankenberg F.G., Berry G.J., Stafford-Cecil S., Tait J.F., et al. In vivo imaging of acute cardiac rejection in human patients using (99m)technetium labeled annexin V. Am J Transp 1 (2001) 270-277
182. Narula J., Acio E.R., Narula N., Samuels L.E., Fyfe B., Wood D., et al. Annexin-V imaging for noninvasive detection of cardiac allograft rejection. Nat Med 7 (2001) 1347-1352
183. Vriens P.W., Blankenberg F.G., Stoot J.H., Ohtsuki K., Berry G.J., Tait J.F., et al. The use of technetium Tc 99m annexin V for in vivo imaging of apoptosis during cardiac allograft rejection. J Thorac Cardiovasc Surg 116 (1998) 844-853